BARCELONA, Spain — European urologic oncologists should prepare themselves for a "tsunami" of magnetic resonance imaging (MRI) in cases of suspected prostate cancer, investigators from the Netherlands ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Biparametric MRI, which omits the dynamic contrast enhancement sequence, can detect clinically significant prostate cancer as well as multiparametric MRI. Biparametric MRI performs as well as ...

The NHS is embarking on a trial that could cut prostate cancer diagnosis times from weeks to a single day. The initiative ...

The American Cancer Society estimates that 288,300 new cases of prostate cancer will be diagnosed in 2023. While the overall 5-year survival rate is 97%, that number goes down significantly if the ...

Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of ...

A trial found no meaningful difference in detection of clinically significantly prostate cancer between multiparametric MRI-based and microultrasound-based biopsy techniques.

Traditionally prostate cancers have been diagnosed using biopsies of the tumour masses. New research from researchers at University College London (UCL) has shown that a more accurate diagnostic means ...